Lymphoma development in Sjögren's syndrome: novel p53 mutations.

OBJECTIVE Sjögren's syndrome (SS) is a chronic autoimmune disease characterized by lymphocytic infiltrations of the exocrine glands. Disease progression may lead to uncontrolled clonal proliferation of B lymphocytes and development of lymphoma. This study was undertaken to examine the possible involvement of the cell cycle checkpoint genes p53 and p21 in the pathophysiology of the syndrome. METHODS Protein expression of p53 and p21 was studied, by immunohistochemistry and Western blot analysis, in minor salivary gland (MSG) biopsy specimens from 7 patients with SS and 5 control subjects. In addition, sequence analysis of the p53 gene was performed on DNA samples obtained from MSG biopsy samples of the same 7 patients with SS and from 4 patients with SS and in situ non-Hodgkin's lymphoma (NHL). RESULTS The study revealed increased protein expression of p53 and p21 in MSG biopsy specimens from patients as compared with controls, while sequence analysis showed that the p53 gene was of the wild type. Furthermore, sequence analysis of the p53 gene from patients with SS and in situ NHL revealed 2 novel mutations in exon 5 of the p53 gene. These mutations are single-base substitutions and appear to be functional since exon 5 is included in the coding region of the p53 gene. CONCLUSION This is the first report on wild-type p53 gene activation in SS. Our findings indicate a probable role for the DNA damage response genes in the pathogenesis of this syndrome. The novel mutations of the p53 gene implicate dysregulation of this tumor suppressor gene as a possible mechanism for lymphoma development in SS.

[1]  David Beach,et al.  p21 is a universal inhibitor of cyclin kinases , 1993, Nature.

[2]  S. Elledge,et al.  Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Hartwell,et al.  Cell cycle control and cancer. , 1994, Science.

[4]  D. Green,et al.  Somatic mutations in the p53 tumor suppressor gene in rheumatoid arthritis synovium. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Cunningham,et al.  p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. , 1995, Oncogene.

[6]  C. Purdie,et al.  Thymocyte apoptosis induced by p53-dependent and independent pathways , 1993, Nature.

[7]  J. Trent,et al.  WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[8]  Thea D. Tlsty,et al.  Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53 , 1992, Cell.

[9]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[10]  J. Cayuela,et al.  Lymphomas in Patients With Sjögren's Syndrome Are Marginal Zone B-Cell Neoplasms, Arise in Diverse Extranodal and Nodal Sites, and Are Not Associated With Viruses , 1997 .

[11]  I. Toda,et al.  Gender and androgen treatment influence the expression of proto-oncogenes and apoptotic factors in lacrimal and salivary tissues of MRL/lpr mice. , 1998, Clinical immunology and immunopathology.

[12]  J. R. Smith,et al.  Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. , 1994, Experimental cell research.

[13]  Theocharis,et al.  Modes of epithelial cell death and repair in Sjögren's syndrome (SS) , 1998, Clinical and experimental immunology.

[14]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[15]  D. Isenberg,et al.  Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. , 1993, Arthritis and rheumatism.

[16]  S. Hinrichs,et al.  Exocrinopathy resembling Sjögren's syndrome in HTLV-1 tax transgenic mice , 1989, Nature.

[17]  N. Miyasaka,et al.  Fine epitope mapping of the human SS-B/La protein. Identification of a distinct autoepitope homologous to a viral gag polyprotein. , 1990, The Journal of clinical investigation.

[18]  N. Ogawa,et al.  Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. , 1997, Arthritis and rheumatism.

[19]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[20]  D. Thorley-Lawson,et al.  A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.

[21]  E. Jaffe,et al.  c-myc mRNA expression in minor salivary glands of patients with Sjögren's syndrome. , 1992, The Journal of rheumatology.

[22]  P. Pisa,et al.  High frequency of t(14;18) translocation in salivary gland lymphomas from Sjogren's syndrome patients , 1991, The Journal of experimental medicine.

[23]  R. Byard,et al.  A review of the proliferative capacity of major salivary glands and the relationship to current concepts of neoplasia in salivary glands. , 1990, Oral surgery, oral medicine, and oral pathology.

[24]  H. Moutsopoulos,et al.  Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjögren's syndrome. , 1995, British journal of rheumatology.

[25]  Stephen J. Elledge,et al.  Mice Lacking p21 CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control , 1995, Cell.

[26]  E. White,et al.  Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. , 1993, Genes & development.

[27]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[28]  T. Crook,et al.  p53 is frequently mutated in Burkitt's lymphoma cell lines. , 1991, The EMBO journal.

[29]  R. Weinberg,et al.  Tumor suppressor genes. , 1994, Current opinion in genetics & development.

[30]  L. Crawford,et al.  Characterization of the human p53 gene , 1986, Molecular and cellular biology.

[31]  S. Elledge,et al.  p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells , 1995, Science.

[32]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[33]  T. Daniels.  Labial salivary gland biopsy in Sjögren's syndrome. Assessment as a diagnostic criterion in 362 suspected cases. , 1984, Arthritis and rheumatism.

[34]  H. Moutsopoulos,et al.  Slow viruses and the immune system in the pathogenesis of local tissue damage in Sjögren's syndrome. , 1992, Annals of the rheumatic diseases.

[35]  H. Moutsopoulos,et al.  Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjögren's syndrome. , 1999, Arthritis and rheumatism.

[36]  L. Klareskog,et al.  Epithelial HLA-DR expression and T lymphocyte subsets in salivary glands in Sjögren's syndrome. , 1985, Clinical and experimental immunology.

[37]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.